Diabetes Care, Vol 21, Issue 4 641-648, Copyright © 1998 by American Diabetes Association

ARTICLES

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

RS Elkeles, JR Diamond, C Poulter, S Dhanjil, AN Nicolaides, S Mahmood, W Richmond, H Mather, P Sharp and MD Feher
St. Mary's Hospital, London, U.K.

OBJECTIVE: To determine whether serum lipid intervention, in addition to conventional diabetes treatment, could alter cardiovascular outcomes in type 2 diabetes. RESEARCH DESIGN AND METHODS: There were 164 type 2 diabetic subjects (117 men, 47 women) without a history of clinical cardiovascular disease randomized to receive either bezafibrate or placebo daily on a double-blind basis in addition to routine diabetes treatment and followed prospectively for a minimum of 3 years. Serial biochemical and noninvasive vascular assessments, carotid and femoral artery B-mode ultrasound measurements, and those pertaining to coronary heart disease (CHD)--clinical history, the World Health Organization (WHO) cardiovascular questionnaire, and resting and exercise electrocardiogram (ECG)--were recorded. RESULTS: Bezafibrate treatment was associated with significantly greater reductions over 3 years in median serum triglyceride (-32 vs. 4%, P = 0.001), total cholesterol (-7 vs. -0.3%, P = 0.004), and total-to-HDL cholesterol ratio (-12 vs. -0.0%, P = 0.001), and an increase in HDL cholesterol (6 vs. -2%, P = 0.02) as compared with placebo. There was a trend toward a greater reduction of fibrinogen (-18 vs. -6%, P = 0.08) at 3 years. No significant differences between the two groups were found in the progress of ultrasonically measured arterial disease. In those treated with bezafibrate, there was a significant reduction (P = 0.01, log-rank test) in the combined incidence of Minnesota-coded probable ischemic change on the resting ECG and of documented myocardial infarction. CONCLUSIONS: Improving dyslipidemia in type 2 diabetic subjects had no effect on the progress of ultrasonically measured arterial disease, although the lower rate of "definite CHD events" in the treated group suggests that this might result in a reduction in the incidence of coronary heart disease.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Hiukka, J. Westerbacka, E. S. Leinonen, H. Watanabe, O. Wiklund, L. M. Hulten, J. T. Salonen, T.-P. Tuomainen, H. Yki-Jarvinen, A. C. Keech, et al. Long-Term Effects of Fenofibrate on Carotid Intima-Media Thickness and Augmentation Index in Subjects With Type 2 Diabetes Mellitus J. Am. Coll. Cardiol., December 16, 2008; 52(25): 2190 - 2197. [Abstract] [Full Text] [PDF]

				X. Ruan, F. Zheng, and Y. Guan PPARs and the kidney in metabolic syndrome Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1032 - F1047. [Abstract] [Full Text] [PDF]

				S. R. Freeman, A. L. Drake, L. F. Heilig, M. Graber, K. McNealy, L. M. Schilling, and R. P. Dellavalle Statins, Fibrates, and Melanoma Risk: a Systematic Review and Meta-analysis. J Natl Cancer Inst, November 1, 2006; 98(21): 1538 - 1546. [Abstract] [Full Text] [PDF]

				H. Yokoyama, N. Katakami, and Y. Yamasaki Recent Advances of Intervention to Inhibit Progression of Carotid Intima-Media Thickness in Patients With Type 2 Diabetes Mellitus Stroke, September 1, 2006; 37(9): 2420 - 2427. [Abstract] [Full Text] [PDF]

				M J. Chapman Review: Fibrates: therapeutic review The British Journal of Diabetes & Vascular Disease, January 1, 2006; 6(1): 11 - 19. [Abstract] [PDF]

				M. D Feher and R. S Elkeles Fenofibrate in type 2 diabetes: The FIELD study: Fibrate Intervention and Event Lowering in Diabetes (FIELD) The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 330 - 333. [PDF]

				L. F Van Gaal, F. Peiffer, and D. Ballaux Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 344 - 350. [Abstract] [PDF]

				B. Staels and J.-C. Fruchart Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists Diabetes, August 1, 2005; 54(8): 2460 - 2470. [Abstract] [Full Text] [PDF]

				A. Tenenbaum, M. Motro, E. Z. Fisman, D. Tanne, V. Boyko, and S. Behar Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome Arch Intern Med, May 23, 2005; 165(10): 1154 - 1160. [Abstract] [Full Text] [PDF]

				B. Cariou, J.-C. Fruchart, and B. Staels Review: Vascular protective effects of peroxisome proliferator-activated receptor agonists The British Journal of Diabetes & Vascular Disease, May 1, 2005; 5(3): 126 - 132. [Abstract] [PDF]

				E. D. Beishuizen, M. A. van de Ree, J. W. Jukema, J. T. Tamsma, and M. V. Huisman Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients With Type 2 Diabetes Without Manifest Cardio-vascular Disease: Response to Cicero et al. Diabetes Care, May 1, 2005; 28(5): 1263 - 1264. [Full Text] [PDF]

				R. S. Birjmohun, B. A. Hutten, J. J.P. Kastelein, and E. S.G. Stroes Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials J. Am. Coll. Cardiol., January 18, 2005; 45(2): 185 - 197. [Abstract] [Full Text] [PDF]

				E. D. Beishuizen, M. A. van de Ree, J. W. Jukema, J. T. Tamsma, J. C. M. van der Vijver, A. E. Meinders, H. Putter, and M. V. Huisman Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients With Type 2 Diabetes Without Manifest Cardiovascular Disease Diabetes Care, December 1, 2004; 27(12): 2887 - 2892. [Abstract] [Full Text] [PDF]

				G. Imperatore, B. L. Cadwell, L. Geiss, J. B. Saadinne, D. E. Williams, E. S. Ford, T. J. Thompson, K. M. Venkat Narayan, and E. W. Gregg Thirty-year Trends in Cardiovascular Risk Factor Levels among US Adults with Diabetes: National Health and Nutrition Examination Surveys, 1971-2000 Am. J. Epidemiol., September 15, 2004; 160(6): 531 - 539. [Abstract] [Full Text] [PDF]

				M. D Feher Beyond LDL lowering: the role of dyslipidaemia and inflammation The British Journal of Diabetes & Vascular Disease, May 1, 2003; 3(3): 157 - 159. [PDF]

				G. Steiner DAIS: how it relates to other lipid intervention studies in diabetes The British Journal of Diabetes & Vascular Disease, May 1, 2003; 3(3): 212 - 215. [Abstract] [PDF]

				R. Harris, K. Donahue, S. S. Rathore, P. Frame, S. H. Woolf, and K. N. Lohr Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, February 4, 2003; 138(3): 215 - 229. [Abstract] [Full Text] [PDF]

				A. D. Mooradian Cardiovascular Disease in Type 2 Diabetes Mellitus: Current Management Guidelines Arch Intern Med, January 13, 2003; 163(1): 33 - 40. [Abstract] [Full Text] [PDF]

				P. Ballinger Do all diabetic patients need statins? A view from primary care The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1): 58 - 61. [Abstract] [PDF]

				H. B. Rubins, S. J. Robins, D. Collins, D. B. Nelson, M. B. Elam, E. J. Schaefer, F. H. Faas, J. W. Anderson, and for the VA-HIT Study Group Diabetes, Plasma Insulin, and Cardiovascular Disease: Subgroup Analysis From the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Arch Intern Med, December 9, 2002; 162(22): 2597 - 2604. [Abstract] [Full Text] [PDF]

				O. Barbier, I. P. Torra, Y. Duguay, C. Blanquart, J.-C. Fruchart, C. Glineur, and B. Staels Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., May 1, 2002; 22(5): 717 - 726. [Abstract] [Full Text] [PDF]

				R. S Elkeles, M. Flather, M. D Feher, I. Godsland, W. Richmond, S. E Humphries, M. B Rubens, and S R. Underwood Prospective evaluation of diabetic ischaemic heart disease by computed tomography: the PREDICT study The British Journal of Diabetes & Vascular Disease, January 1, 2002; 2(1): 69 - 72a. [Abstract] [PDF]

				M. J. Franz, J. P. Bantle, C. A. Beebe, J. D. Brunzell, J.-L. Chiasson, A. Garg, L. A. Holzmeister, B. Hoogwerf, E. Mayer-Davis, A. D. Mooradian, et al. Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications Diabetes Care, January 1, 2002; 25(1): 148 - 198. [Full Text] [PDF]

				F. Berthezene Diabetic dyslipidaemia The British Journal of Diabetes & Vascular Disease, January 1, 2002; 2(1_suppl): S12 - S17. [Abstract] [PDF]

				M. Pignone, C. Phillips, and C. Mulrow Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials BMJ, October 21, 2000; 321(7267): 983 - 986. [Abstract] [Full Text]

				H. J Milionis, A. F Winder, and D. P Mikhailidis Lipoprotein (a) and stroke J. Clin. Pathol., July 1, 2000; 53(7): 487 - 496. [Abstract] [Full Text] [PDF]

				L. H. Kuller, P. Velentgas, J. Barzilay, N. J. Beauchamp, D. H. O’Leary, and P. J. Savage Diabetes Mellitus : Subclinical Cardiovascular Disease and Risk of Incident Cardiovascular Disease and All-Cause Mortality Arterioscler. Thromb. Vasc. Biol., March 1, 2000; 20(3): 823 - 829. [Abstract] [Full Text] [PDF]

				M D FEHER and R S ELKELES Lipid modification and coronary heart disease in type 2 diabetes: different from the general population? Heart, January 1, 1999; 81(1): 10 - 11. [Full Text]